Pasithea Therapeutics Corp. - 8-K Filing

Pasithea Therapeutics reports positive Phase 1/1b clinical data for PAS-004 and receives FDA IND clearance for Phase 2 trial. (Items: 7.01 Regulation FD On November 13, 2026, Pasithea Therapeutics Corp, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $KTTA

Read the full article at SEC EDGAR

More Regulatory news